Sosei Signs Distribution Agreement with FUJIFILM Pharma
News Feb 08, 2014
Sosei Group Corporation has announced that its Japanese subsidiary, Sosei Co., Ltd., (“Sosei K.K.”) has signed a distribution agreement for commercialization of SO-1105 in Japan with FUJIFILM Pharma Co., Ltd (“FUJIFILM Pharma”).
SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. It has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients’ compliance and quality of life.
SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006.
SO-1105 has since been registered in 24 European countries, in South Korea, and in the United States, under the trade names Loramyc®/Oravig®. Sosei K.K. acquired exclusive development and commercialization rights in Japan from BioAlliance in May 2011.
Under the terms of the agreement with FUJIFILM Pharma, Sosei K.K. will be responsible for registration, manufacturing and supply, and FUJIFILM Pharma for marketing and distribution of SO-1105.
Based on this agreement, Sosei K.K. is entitled to receive a total of 900 million yen for key initial payment and achieved development and regulatory milestones, as well as margin on the sales of SO-1105 to FUJIFILM Pharma. Additional payments may also be received upon achievement of sales-based milestones.
We believe that the distribution agreement with FUJIFILM Pharma, which has expertise in infectious diseases, will help us expand the reach of SO-1105 to more oropharyngeal candidiasis patients.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018